Why is the RCF needed?

There are currently inequalities of care and support facing cancer patients in the UK. For example, where the patient lives, how long it takes to achieve a diagnosis, and availability of treatment. These inequalities can have an enormous effect on a patient’s quality of life, and, ultimately, on their prognosis.

Rarer Cancers

There are hundreds of different types of cancer, and research suggests that between 30% and 50% of all cancer cases could be classified as ‘rarer’. They fall outside the more common and highly publicised cancers such as colon, breast, lung and prostate.

A cancer may be classed as ‘rarer’ either because it affects an unusual site in the body, or because the cancer itself is of an unusual type, or requires special treatment.

However, the most important feature of a rarer cancer is the fact that the patient feels isolated. There may be few survivors, or no available support network. The GP may know very little about the condition, and it is difficult to get accurate information about the prognosis or the effect of treatment.

“We ensure that people with rarer cancers have access to the best services and outcomes”

The Rarer Cancers Foundation exists to ensure that people with rarer cancers have access to the best services and outcomes.

  • We provide up to date information on rarer cancers and treatment options available
  • We enable supportive networking for patients, carers and clinicians
  • We act as a gateway, directing patients to further avenues of support and information, such as patient groups or charities
  • We raise awareness about the less common cancers
  • We give a voice to ‘forgotten’ cancers
  • We produce information literature for both patients and healthcare professionals
  • We campaign for change at government level to secure the best possible patient journey for people living with rarer cancers.

cloudRarer Cancers Foundation Campaign and Awareness News

2013 has seen a 2 year extention to the Cancer Drugs Fud which has treated over 45,000 patients to date. With the Indroduction of NHS England to the Health Service the charity continues to campaign for better services and treatments for Cancer patients in England, Scotland, Wales and Northern Ireland. Key highlights include :

  • Ensuring that the Cancer Drugs Fund is adequately resourced, achieving a total of £650 million in funding over three and half years
  • Achieving recognition of the importance of near-label prescribing and its inclusion within the parameters of the Cancer Drugs Fund